

SAMPLE REPORT 01-Jun-1984 Female

P: +1.206.365.1256 E: cservice@usbiotek.com 1620 Linden Av N Shoreline WA, 98133

-.- US BIOTEK

LAB ID: 4001555 Accession #: 300002222222

Collection Date: 27-Mar-2025 Practitioner:

Request Date: 30-Mar-2025 SAMPLE REPORT, ND

Vaginal Microbiome Profile

3.5 - 4.5Vaginal pH. 4.8 *H Methodology: Testing performed by PCR, qPCR and MALDI-TOF Opportunistic Bacteria Result Range **Units Enterococcus faecalis:** 10.00 *H < 1.0 x10⁵ CFU/ml Escherichia coli: <DL < 1.00 x10^5 CFU/ml Klebsiella pneumoniae: <DL < 1.00 x10⁵ CFU/ml **Proteus mirabilis:** <DL < 1.00 x10⁵ CFU/ml Pseudomonas aeruginosa: <DL < 1.00 x10^5 CFU/ml Streptococcus agalactiae: <DL < 1.00 x10^5 CFU/ml Staphylococcus aureus: <DL < 1.00 x10^5/CFU/ml Gardnerella vaginalis: <DL < 1.00 x10^5 CFU/ml Atopobium vaginae: <DL < 1.00 x10^5 CFU/ml <DL/ Prevotella species: < 1.00 x10⁵ CFU/ml Megasphaera species: <DL < 1.00 x10^5 CFU/ml **Ureaplasma** species <DL < 1.00 x10^6 CFU/ml Mycoplasma species <DL < 1.00 x10^6 CFU/ml Sexually Transmitted Infections Trichomonas vaginalis: Not Detected COMMENT: Chlamydia trachomatis: Not Detected Not Detected results indicate the absence of Neisseria gonorrhoeae: Not Detected detectable DNA in this sample. A negative **Herpes Simplex Virus-1:** Not Detected result does not completely exclude infection. **Herpes Simplex Virus-2: Not Detected** Opportunistic Fungal pathogens Candida albicans: <DL < 1.00 x10⁵ CFU/ml Candida glabrata: <DĽ < 1.00 x10^5 CFU/ml Candida krusei: ≺ĎĿ < 1.do x10^5 CFU/ml Candida parapsilosis: <DL < 1.00 x10⁵ CFU/ml Candida tropicalis: <DL < 1.00 x10^5 CFU/ml Beneficial Bacteria: **Total Lactobacillus:** 0.40 *L > 1.00 x10⁶ CFU/ml Lactobacillus crispatus: 0.30 *L > 1.00 x10^6 CFU/ml Lactobacillus gasseri: <DL *L > 1.00 x10⁶ CFU/ml Lactobacillus iners: <DL *L > 1.00 x10⁶ CFU/ml Lactobacillus jensenii: 0.10 *L > 1.00 x10^6 CFU/ml Lactobacillus rhamnosus: <DL *L > 1.00 x10^6 CFU/ml Lactobacillus salivarius: <DL *L > 1.00 x10⁶ CFU/ml Lactobacillus vaginalis: <DL *L > 1.00 x10⁶ CFU/ml **Bacterial Vaginosis:**

Bacterial vaginosis Negative

Page 1 of 3 Final Report Printed:April 14, 2025



01-Jun-1984 **Female**

P: +1.206.365.1256 E: cservice@usbiotek.com 1620 Linden Av N Shoreline WA, 98133

-.- US BIOTEK

300002222222 LAB ID: 4001555 Accession #:

Collection Date: 27-Mar-2025 **Practitioner:**

Request Date: 30-Mar-2025 SAMPLE REPORT, ND

Vaginal Microbiome Comments

VAGINAL pH ELEVATED:

Vaginal pH can be elevated by the presence of pathogenic infection, blood, semen, vaginal medications, using certain soaps and douches. In the absence of the latter, an elevated pH may be the result of decreased serum oestradiol and is suggestive of menopause or hormone imbalance and may require further pathology investigation.

The typical vaginal pH is 3.5-4.5. Prepubertal and postmenopausal pH levels are normally >5 pH. With the increase of the oestrogen levels around puberty, the genital mucosa thickens and becomes colonized with Lactobacillus species which produce lactic acid and hydrogen peroxide to lower the pH below 4.5. References:

Caillouette et. al., 1997, American Journal of Obstetrics and Gynaecology, 176(6)1270-1277.

Panda et. al., 2014, Journal of Mid-Life Health, 5(1):34-37.

Kaambo et. al., 2018, Front Public Health, 6:78.

AEROBIC VAGINITIS (AV):

Patients suffering AV may experience vaginal complaints such as abnormal discharge (yellowish), inflammation (redness and swelling), and/or small erosions or ulcerations. If untreated, it can transition into more serious complications (PID, dyspareunia [pain during intercourse], severe UTIs, and/or pregnancy complications). Causes of AV include immune dysregulation, low oestrogen or Vitamin D deficiency.

There is no accepted clinical strategy for treating AV. Treatment with either antiseptic or antibiotic therapy with emphasis on bacteria of faecal origin, whilst ensuring minimal interference with vaginal Lactobacillus species.

ENTEROCOCCUS FAECALIS ELÈVATED:

Enterococcus faecalis is a Gram-positive commensal bacterium native to the gastrointestinal tract and an opportunistic pathogen of increasing clinical concern. E. faecalis also colonizes the female reproductive tract, and reports suggest vaginal colonization increases following antibiotic treatment or in patients with AV. While vaginal E. faecalis colonization is normally asymptomatic, certain populations may be at risk for severe disease. AV is defined by disruption in Lactobacillus dominance (Total Lactobacillus <10^6 CFU/ml), increased pH (>4.5) and the presence of mainly aerobic enteric commensals or pathogens, including Enterococcus faecalis (>10^5 CFU/ml).

LACTOBACILLUS:

Lactobacillus is the predominant genus in a healthy vaginal microbiota, and functions to inhibit the adhesion and proliferation of opportunistic and primary pathogens,

The presence of different Lactobacillus species is a major factor in the stability of the vaginal microbiome. Women with L. iners-dominant microbiomes are more likely to harbor Candida than women with L. crispatus-dominant microbiomes (due to higher production of lactic acid by L. crispatus compared to L. iners), leading to better anti-Candida activity (impeding Candida colonization) than L. iners through a greater production of lactic acid. Furthermore, L. iners dominance has been associated with other negative health outcomes such as increased risks of Chlamydia trachomatis infection, incident Bacterial Vaginosis and defects in vaginal mucus that compromise antiviral barrier function.

TOTAL LACTOBACILLUS LEVELS LOW:

Total Lactobacillus quantification should be >1x10^6 CFU/ml in a healthy Vaginal Microbiome. Production of H2O2 by Lactobacillus species is essential in inhibiting the overgrowth of pathogens. In cases where total Lactobacillus levels are low, presence of pathogenic bacteria should be reviewed and probiotic therapy should be considered. Microorganisms not belonging to the Lactobacillus genus with the population equal to or greater than 1x 10^5 CFU/ml is considered to be disturbing the vaginal ecosystem equilibrium.

References:

Pacha-Herrera et. al., 2020, Frontiers in Cellular and Infection Microbiology, 10:303.

Oerlemans et. al.,2020, Europe PMC, 10(11).

Tomusiak et. al., 2013, Polish Society of Gynaecologists, 84:352-358.

Printed:April 14, 2025 Page 2 of 3 **Final Report**



BioTek SAMPLE REPORT ORATORIES 01-Jun-1984 Female

P: +1.206.365.1256 E: cservice@usbiotek.com 1620 Linden Av N Shoreline WA, 98133

-.- US BIOTEK

LAB ID: 4001555 Accession #: 30000222222

Collection Date: 27-Mar-2025 Practitioner:

Request Date: 30-Mar-2025 SAMPLE REPORT, ND

DISCLAIMER:

Any information provided by us is for information purposes only.

Commentary is provided to the practitioner for educational purposes and should not be interpreted as diagnostic or as treatment recommendations. Diagnosis and treatment decisions are the practitioner's responsibility.

Testing performed by: NutriPATH Pathology 16 Harker Street, Burwood 3125 AU. Lab Director: Jillian Harrington, PhD, HCLD (ABS). CLIA#99D2282774

Sex. Transmitted Infection Comments

TRICHOMONAS VAGINALIS - Not Detected:

This does not completely exclude the possibility of infection as is dependent on an adequate specimen collection. If you have symptoms, please consult with your healthcare practitioner.

CHLAMYDIA TRACHOMATIS - Not Detected:

This does not completely exclude the possibility of infection as is dependent on an adequate specimen collection. If you have symptoms, please consult with your healthcare practitioner.

NEISSERIA GONORRHOEAE - Not Detected:

This does not completely exclude the possibility of infection as is dependent on an adequate specimen collection. If you have symptoms, please consult with your healthcare practitioner.

HERPES SIMPLEX VIRUS Type 1 – Not Detected:

This does not completely exclude the possibility of infection as is dependent on an adequate specimen collection. If you have symptoms, please consult with your healthcare practitioner.

HERPES SIMPLEX VIRUS Type 2 – Not Detected:

This does not completely exclude the possibility of infection as is dependent on an adequate specimen collection. If you have symptoms, please consult with your healthcare practitioner.



Page 3 of 3 Final Report Printed:April 14, 2025